Patent intelligence · Companies
Company patent strength
Non-educational filers ranked by their patent portfolio. Grant rate and lapsed share expose where high filing volume is not matched by granted patents. Domestic filers lead — toggle to foreign applicants to see who is entering the Indian market.
Free to browse the ranking. Sign into open a filer's full profile — inventors, filing trend and quality index. See how we rank.
Why this page exists — and how to read it
Filing volume and IP quality are different things. This leaderboard ranks non-educational filers by portfolio, but the grant-rate and lapsed sorts are where the judgement lives: they separate companies whose filings survive examination from those accumulating paper.
- Investors
- High grant rate on steady filing usually means a real R&D engine; big volume with a high lapsed share is a red flag worth asking about.
- Founders & operators
- These are the incumbents and potential acquirers in your space — open a filer to see the walls you'd build against.
- Corporate & R&D
- Benchmark competitors' portfolios and grant rates; toggle to foreign to watch who is entering the Indian market.
💬 The grant-rate sort applies a 20-filing floor so tiny portfolios can't top the list.
3,207 foreign filers with 5+ patents · page 44
| # | Filer | Patents↓ | Granted↓ | Lapsed↓ | Pending↓ | Active |
|---|---|---|---|---|---|---|
| 2151 | RUBBLE MASTER HMH | 7 | 00% | 2 | 5 | 2022–2022 |
| 2152 | S I P A SOCIETA INDUSTRIALIZZAZIONE PROGETTAZIONE E AUTOMAZIONE | 7 | 00% | 0 | 7 | 2022–2026 |
| 2153 | SABIC SK NEXLENE | 7 | 342.9% | 0 | 4 | 2022–2024 |
| 2154 | SAIL BIOMEDICINES | 7 | 00% | 0 | 7 | 2024–2026 |
| 2155 | SAINT GOBAIN ADFORS | 7 | 114.3% | 0 | 6 | 2022–2025 |
| 2156 | SALTIGO | 7 | 457.1% | 0 | 3 | 2022–2025 |
| 2157 | SARTORIUS BIOHIT LIQUID HANDLING | 7 | 114.3% | 0 | 6 | 2021–2024 |
| 2158 | SCHENCK PROCESS AUSTRALIA PTY | 7 | 00% | 3 | 4 | 2023–2023 |
| 2159 | SELECTA BIOSCIENCES | 7 | 00% | 2 | 5 | 2022–2023 |
| 2160 | SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE | 7 | 00% | 1 | 6 | 2023–2026 |
| 2161 | SHANGHAI SENHUI MEDICINE | 7 | 00% | 0 | 7 | 2022–2025 |
| 2162 | SHANGHAI ZHIMENG BIOPHARMA | 7 | 342.9% | 0 | 4 | 2022–2024 |
| 2163 | SHELTERED WINGS D B A VORTEX OPTICS | 7 | 114.3% | 0 | 6 | 2021–2025 |
| 2164 | SHENYANG SINOCHEM AGROCHEMICALS R D | 7 | 571.4% | 0 | 2 | 2022–2025 |
| 2165 | SHENZHEN CHIPSCREEN BIOSCIENCES | 7 | 00% | 2 | 5 | 2022–2025 |
| 2166 | SHENZHEN SKYWORTH RGB ELECTRONIC | 7 | 114.3% | 5 | 1 | 2022–2023 |
| 2167 | SHENZHEN TCL NEW TECHNOLOGY | 7 | 114.3% | 0 | 6 | 2020–2026 |
| 2168 | SHIFAMED HOLDINGS | 7 | 00% | 0 | 7 | 2023–2025 |
| 2169 | SICONA BATTERY TECHNOLOGIES PTY | 7 | 00% | 0 | 7 | 2022–2025 |
| 2170 | SIGNODE INDUSTRIAL GROUP | 7 | 00% | 0 | 7 | 2024–2026 |
| 2171 | SINOMA WIND POWER BLADE | 7 | 00% | 0 | 7 | 2025–2026 |
| 2172 | SINOMECH | 7 | 00% | 0 | 7 | 2023–2025 |
| 2173 | SISAF | 7 | 00% | 0 | 7 | 2024–2025 |
| 2174 | SK BIOPHARMACEUTICALS | 7 | 342.9% | 0 | 4 | 2022–2024 |
| 2175 | SK BIOSCIENCE | 7 | 00% | 0 | 7 | 2022–2024 |
| 2176 | SKF LUBRICATION SYSTEMS GERMANY | 7 | 00% | 0 | 7 | 2023–2026 |
| 2177 | SNAP | 7 | 457.1% | 0 | 3 | 2022–2025 |
| 2178 | SODASTREAM INDUSTRIES | 7 | 00% | 0 | 7 | 2022–2026 |
| 2179 | STAEDTLER SE | 7 | 342.9% | 0 | 4 | 2022–2025 |
| 2180 | STIESDAL HYDROGEN A S | 7 | 114.3% | 0 | 6 | 2023–2026 |
| 2181 | SUMITOMO BAKELITE | 7 | 00% | 1 | 6 | 2022–2025 |
| 2182 | SWALLOW INCUBATE | 7 | 114.3% | 4 | 2 | 2022–2022 |
| 2183 | T EN PROCESS TECHNOLOGY | 7 | 00% | 0 | 7 | 2022–2025 |
| 2184 | TAS GLOBAL | 7 | 00% | 0 | 7 | 2023–2024 |
| 2185 | TECNOMATIC | 7 | 00% | 0 | 7 | 2022–2025 |
| 2186 | TEH YOR | 7 | 00% | 0 | 7 | 2022–2025 |
| 2187 | TENEOBIO | 7 | 00% | 0 | 7 | 2022–2024 |
| 2188 | TENNECO | 7 | 228.6% | 0 | 5 | 2022–2025 |
| 2189 | THYSSENKRUPP MARINE SYSTEMS | 7 | 342.9% | 0 | 4 | 2022–2025 |
| 2190 | TOKO YAKUHIN KOGYO | 7 | 00% | 2 | 5 | 2022–2024 |
| 2191 | TOWARDPI BEIJING MEDICAL TECHNOLOGY | 7 | 00% | 0 | 7 | 2024–2026 |
| 2192 | TOYO DENSO | 7 | 342.9% | 0 | 4 | 2019–2025 |
| 2193 | TSUBOTA LABORATORY | 7 | 00% | 0 | 7 | 2022–2026 |
| 2194 | TUBULIS | 7 | 00% | 0 | 7 | 2024–2026 |
| 2195 | TYCO FIRE PRODUCTS LP | 7 | 457.1% | 2 | 1 | 2021–2023 |
| 2196 | UBIPROTEIN | 7 | 00% | 0 | 7 | 2023–2023 |
| 2197 | UNIGEN | 7 | 00% | 3 | 4 | 2022–2023 |
| 2198 | UNIPHY | 7 | 00% | 0 | 7 | 2022–2025 |
| 2199 | UPKARA | 7 | 114.3% | 0 | 6 | 2021–2026 |
| 2200 | USHUR | 7 | 228.6% | 0 | 5 | 2022–2026 |
Educational institutes are excluded — see the institute leaderboard. Attribution is by patent assignee record; a jointly-owned patent is credited to each co-owner, so a co-filed patent counts for every company on it. "Lapsed" = abandoned, withdrawn, deemed-withdrawn or refused; "Pending" = awaiting examination or in prosecution. Want to filter by technology or value category? Browse the filer explorer →
Rankings use patent-registry status (grant rate, examination, claim depth) as a quality proxy — directional, not advice; see methodology. Read the ranking methodology →